Atara Biotherapeutics Net Worth
Atara Biotherapeutics Net Worth Breakdown | ATRA |
Atara Biotherapeutics Net Worth Analysis
Atara Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Atara Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Atara Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Atara Biotherapeutics' net worth analysis. One common approach is to calculate Atara Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Atara Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Atara Biotherapeutics' net worth. This approach calculates the present value of Atara Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Atara Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Atara Biotherapeutics' net worth. This involves comparing Atara Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Atara Biotherapeutics' net worth relative to its peers.
To determine if Atara Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Atara Biotherapeutics' net worth research are outlined below:
| Atara Biotherapeutics generated a negative expected return over the last 90 days | |
| Atara Biotherapeutics has high historical volatility and very poor performance | |
| Atara Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 128.94 M. Net Loss for the year was (85.4 M) with loss before overhead, payroll, taxes, and interest of (39.8 M). | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (68.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Roughly 22.0% of the company shares are held by company insiders |
Atara Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Atara Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atara Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Atara Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.49 M.Project Atara Biotherapeutics' profitablity
The company has Profit Margin (PM) of (0.66) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.37) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.37.When accessing Atara Biotherapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Atara Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Atara Biotherapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atara Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atara Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atara Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atara Biotherapeutics time-series forecasting models is one of many Atara Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atara Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Atara Biotherapeutics Earnings per Share Projection vs Actual
Atara Biotherapeutics Corporate Management
| Rajani MD | Senior Officer | Profile | |
| Eric Hyllengren | Executive Officer | Profile | |
| Jakob MD | Ex RD | Profile | |
| Kerry Daly | Head Communications | Profile | |
| Jill Henrich | Executive Quality | Profile | |
| Utpal MBA | Ex CFO | Profile | |
| Alex Chapman | Vice Relations | Profile |
Already Invested in Atara Biotherapeutics?
The danger of trading Atara Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atara Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atara Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atara Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.